Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: Report of a case

Oncology

Volumn 61, Issue 1, 2001, Pages 16-22

  Iwahashi, Makoto ^a   Nakamori, Mikihito ^a   Tani, Masaji ^a   Yamaue, Hiroki ^a   Sakaguchi, Satoru ^a   Nakamura, Masaki ^a   Ueda, Kentaro ^a   Ichiro, Matsuura ^a   Nishino, Eisei ^a   Tanimura, Hiroshi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; Complete response; Gastric cancer, advanced; Low dose; Neoadjuvant chemotherapy; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; TS 1;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER REGRESSION; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; PERITONEAL DISEASE; PERITONEUM TUMOR; PRIORITY JOURNAL; STOMACH CANCER; TUMOR BIOPSY;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; GASTRECTOMY; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OXONIC ACID; PERITONEAL NEOPLASMS; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 17844397700     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055347     Document Type: Article

References (25)

1. Continuous 5-fluorouracil infusion in advanced gastric carcinoma
2. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study
3. Circadian rhythm-varying plasma concentration of 5-fluorouracil during five days continuous infusion at a constant rate in cancer patients
4. Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
5. Metabolism of 5-fluorouracil in various human normal and tumor tissues
6. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
7. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group
8. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
9. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients
10. Pilot trial of continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer
11. Low-dose continuous infusion 5-fluorouracil and cisplatin: Phase II evaluation in advanced colorectal carcinoma
12. Reporting results of cancer treatment
13. Complete response of a gastric primary after a short but toxic course of S-1
14. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
15. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
16. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer
17. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma
18. Clinical evaluation of hepatic arterial infusion of low dose-CDDP and 5-FU with hyperthermotherapy: A preliminary study for liver metastases from esophageal and gastric cancer
19. Conceptual changes in cancer chemotherapy: From an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan
20. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug
21. FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer
22. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group
23. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)
24. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial
25. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer